That might not be enough to buffer earnings once genericversions of Takedas best-seller, Actos, reach pharmacy shelvesin 2012, said Atsushi Seki, an analyst at Barclays Plc in Tokyo.The diabetes pill accounted for 27 percent of sales last fiscalyear and Hasegawa said on May 11 that competition
Date: May 20, 2011
Category: Business
Source: Google
Takeda to Buy Nycomed for 9.6 Bln Euros to Fill Sales Gap
Takeda is buying time with this acquisition, it was slow to enter emerging markets, said Atsushi Seki, an equities analyst at Barclays Plc in Tokyo. However, its an expensive purchase and may not be enough to make up for revenue that will be lost from Actos.
Date: May 19, 2011
Category: Business
Source: Google
Daiichi Sankyo to Buy Plexxikon for $935 Million, Add Cancer Drugs
Buying Plexxikon may enable Daiichi Sankyo to enter the U.S.cancer-drug market as early as 2012, said Atsushi Seki, anequities analyst at Barclays Plc in Tokyo. Daiichi and itsJapanese rivals Takeda Pharmaceutical Co., Astellas Pharma Inc.and Eisai Co. are buying promising cancer medicines to ta